Board of Directors
The Imunexus Board of Directors, Management and Research and Development teams are experienced personnel with substantial achievements across the fields of drug development and commercialisation of new therapeutics, scientific research, business development and finance.
Collectively, the team have significant experience in the identification, design and development of successful antibody technology platforms and potential antibody products and have a history in establishing strong patent portfolios.
The Company's management team are experienced in deriving value from intellectual property through licensing, mergers and acquisitions within the pharmaceutical industry.
Philippa Lewis is a Professional Company Director, Chairperson and Chief Executive with expertise in the Medtech, Biotech, Digital and Artificial Intelligence sectors.
Philippa has extensive global, commercial and corporate engagement with demonstrated success. Founding over ten start-ups she has led local and North American IPOs, reverse mergers, complex M&A transactions, strategic capital management and multilateral joint ventures within North America, Europe, China and Australia. She was nominated as Zurich Business Leader of the Year and Telstra Business Woman of the Year and is currently an official company mentor for the Australian Technology Competition as well as an appointed grants assessor for the NSW Government Medtech and Pharma Growth Centre.
Philippa is a Graduate of the Australian Institute of Company Directors, The Institute of Public Companies Canada via Simon Fraser University, and The Adelaide University in respect of Legal Arbitration and is a member of the Australian Institute of Company Directors, The MTAA, The Institute of Arbitrators and Mediators and The Resolution Institute.
Non Executive Director
John Gaffney is an experienced Non-Executive Director with a demonstrated history as a NED in the pharmaceuticals industry and financial technology sector. John is a lawyer with over 30 years of experience with a Master of Laws from Monash University. He has a compliance and corporate governance background and is experienced in financial services compliance. He also has corporate commercial experience having worked with a major international law firm as a senior lawyer and practised as a barrister at the Victorian Bar. John is a Graduate of AICD and is currently a Non-executive Director of Paradigm Biopharmaceuticals (ASX: PAR). John was previously a director of SelfWealth Ltd ( ASX: SWF) and a director of a US-based biotechnology company.
Don has 30 years’ experience as a senior partner of Ernst & Young, Oceania, has extensive experience in IPO’s, transactions and audit. Don has advised and worked with a number of Boards, ranging from some of the largest in Australia to fast growing entrepreneurial and medium sized organisations. Don was the Oceania IPO Leader at Ernst & Young and worked with clients listing on the AUS, US, UK and key Asian stock exchanges. He held positions as Biotech Markets Leader, National Leader of Strategic Growth Markets and on the Board of Partners of Ernst & Young. He is currently a Non-Executive Director of Acrux Limited (ASX: ACR) and previous Board positions include Bio-Gene Technology Ltd (Chair, ASX:BGT) and Murray River Organics Group Limited (ASX: MRG). Don is a Fellow of Chartered Accountants Australia & New Zealand, a member of the Australian Institute of Company Directors.